Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

OBJECTIVE: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaziano, J. Michael, Cincotta, Anthony H., O'Connor, Christopher M., Ezrokhi, Michael, Rutty, Dean, Ma, Z.J., Scranton, Richard E.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890350/
https://www.ncbi.nlm.nih.gov/pubmed/20332352
http://dx.doi.org/10.2337/dc09-2009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890350/
https://www.ncbi.nlm.nih.gov/pubmed/20332352
http://dx.doi.org/10.2337/dc09-2009

Ejemplares similares